Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a buy rating in a report released on Sunday.

Several other equities research analysts have also recently issued reports on REGN. Zacks Research raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 8th. Oppenheimer reiterated an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research note on Monday, February 2nd. Finally, Scotiabank boosted their price target on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research note on Monday, November 24th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Stock Down 3.3%

NASDAQ REGN opened at $754.91 on Friday. Regeneron Pharmaceuticals has a 52 week low of $476.49 and a 52 week high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The business’s fifty day simple moving average is $758.15 and its 200-day simple moving average is $661.69. The firm has a market cap of $79.34 billion, a PE ratio of 18.16, a P/E/G ratio of 2.10 and a beta of 0.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the prior year, the firm posted $12.07 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is presently 8.47%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.02% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently made changes to their positions in the company. Osaic Holdings Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after buying an additional 6,073 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Regeneron Pharmaceuticals by 153.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock valued at $67,969,000 after acquiring an additional 73,176 shares during the last quarter. PGGM Investments raised its holdings in Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock valued at $52,057,000 after acquiring an additional 8,187 shares during the last quarter. Bellecapital International Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after purchasing an additional 6,283 shares during the period. Finally, Rakuten Investment Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $33,121,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.